Corvus Pharmaceuticals Inc (CRVS)

[muchogusto]

If you read the recent book “for the blood and money”, you will find out that Miller actually had given up on motexafin gadolinium. He was starting the process to develop btki which they had licensed from Solera. At this point Duggan took control of pharmacyclics and insisted on not giving up on motexafin gadolinium. Duggan also replaced the board. Miller lost all control and resigned from the company and sold all his pharmacyclics stock and options. But duggan realized his mistake later on and hired staff to start the btk work. Miller was the brainchild of btki and he was the first one to know its potential. But he unfortunately didn’t benefit from the success of the drug and the pharmacyclic stock.